İsmail DEMİR, Rasim Selçuk YILMAZ, Betül KÖSE, Hüseyin ÖZKARAKAŞ, Şebnem ÇALIK

Relationships between vaccination, age, and mortality in the COVID-19 intensive care patients

Objectives: To investigate the effects of vaccination on age, mortality, and healthcare workers among patients followed in the COVID-19 Intensive Care Unit. Methods: We examined age, gender, occupation, demographic characteristics, comorbid diseases, hemogram, biochemistry parameters, coagulation tests, morbidity–mortality characteristics of 548 patients in Bozyaka Training and Research Hospital COVID-19 intensive care unit admitted between March and October 2021. In addition, the vaccination status of the patients and the type of vaccination were recorded via the Ministry of Health Vaccine Tracking System (VTS). Within the vaccine follow-up system, patients who received at least 2 doses of vaccine 4 weeks prior to study were considered vaccinated. Results: The data of 548 patients in the COVID-19 intensive care unit between March 2021 and October 2021 were analyzed. The mortality rate was 50.7% (n = 278). It was determined that 428 (78.1%) of the patients followed in the COVID-19 intensive care unit were not vaccinated. In terms of age distribution, the number of patients under the age of 65 was 357 (65.1%), while the number of patients aged 65 and over was 191 (34.9%). When mortality rates were compared based on vaccination status, the mortality rate in the unvaccinated group was found to be statistically significantly higher than in the vaccinated group (p < 0.05). Mortality rate in the vaccinated group was 12.5% whereas it was 61.4% in the unvaccinated group. Conclusions: Vaccination to protect against SARS-CoV-2 infection reduces intensive care unit admission and reduces mortality rates. Being unvaccinated increases hospitalization and mortality in intensive care units in addition to carrying risks for all age groups.

Keywords:

COVID-19 intensive care, vaccination, mortality, age, healthcare workers,

PDF

___

1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. https://covid19.who.int/
2. Maamar M, Khibri H, Harmouche H, Ammouri W, Tazi-Mezalek Z, et al. The impact of lockdown on the health of the elderly during the COVID-19 pandemic. NPG Neurol Psychiatr Geriatr 2020;20:322-5.
3. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020;172:577-82.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
6. Ersoy A. The frontline of the COVID-19 pandemic: healthcare workers. Turk J Intern Med 2020;2:31-2.
7. European Centre for Disease Prevention and Control. Corona virus disease 2019 (COVID-19) in the EU/EEA and the UK – eighth update. 2020. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-eighth-update-8-april-2020.pdf
8. World Health Organization (WHO), Geneva, Switzerland. Draftlandscape of COVID-19 candidate vaccines. Available at: https://www.who.int/publications/m/item/draftlandscape-of-covid-19-candidate-vaccines
9. Republic Of Turkey Ministry of Health. https://covid19asi.saglik.gov.tr/?_Dil=2
10. Demirbilek Y, Pehlivantürk G, Özgüler ZÖ, Meşe EA. COVID-19 outbreak control, example of Ministry of Health of Turkey. Turk J Med Sci 2020;50(SI-1):489-94.
11. WHO. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine. https://cdn.who.int/media/docs/defaultsource/immunization/sage/2021/april/5_sage29apr2021_critical-evidence_sinovac.pdf.
12. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Eng J Med 2020;383:2603-15.
13. World Health Organization Technical document. Background document on mRNA vaccine BNT162b2 (Pfizer/BioNTech) against COVID-19. 14 January 2021. https://www.who. int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19
14. Vaccine Tracking System. https://asi.saglik.gov.tr/ats
15. International symposium of World Shaking Pandemic SARS-COV2- and Elderly Health Ege University, Izmir, 2020
16. Guillon A, Laurent E, Godillon L, Kimmoun A, Grammatico-Guillon L. Long-term mortality of elderly patients after intensive care unit admission for COVID-19. Intensive Care Med 2021;47:710-2.
17. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020;323:1775-6.
18. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids in understanding the spread and fatality rates of COVID-19. Proc Natl Acad Sci U S A 2020;117:9696-8.
19. European Centre for Disease Prevention and Control. Corona virüs disease 2019 (COVID-19) in the EU/EEA and the UK – eighth update. 2020. https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-eighth-update-8-april-2020.pdf (accessed 05/05/2020).
20. Mortality Analyses. Johns Hopkins Coronavirus Resource Center n.d. https://coronavirus.jhu.edu/data/mortality. Accessed May 26, 2020.
21. Memory List. List of doctors, nurses, nurses, laboratory assistants and other medical workers who died during the COVID pandemic. 2020. https//sites.google.com/view/covid-memory/home?authuser=0. Accessed May 4, 2020.

ISSN: 2149-3189
Yayın Aralığı: Yılda 6 Sayı
Başlangıç: 2015
Yayıncı: Prusa Medikal Yayıncılık Limited Şirketi

Arşiv